Lipid Nanoparticles in Drug and Gene Delivery: Current Advances and Future Perspectives

As a cutting-edge non-viral delivery system, lipid nanoparticles (LNPs) are revolutionizing the treatment of drugs and nucleic acids. LNPs are now recognized as adaptable, clinically validated nanocarriers due to their clinical success, as evidenced by approved siRNA therapies and extensively used mRNA vaccines. In order to facilitate effective intracellular cargo release, modern LNPs employ ionizable lipids, which are neutral under physiological conditions but become positively charged in acidic endosomes. Stability, encapsulation efficiency, biodistribution, and therapeutic efficacy have all been enhanced by developments in lipid chemistry, microfluidic manufacturing, surface engineering, and artificial intelligence-assisted formulation. However, obstacles to wider use still include low tissue specificity, ineffective endosomal escape, immunogenicity, production difficulties, and long-term safety. The evolution, composition, formulation, delivery methods, therapeutic uses, clinical translation, regulatory issues, and upcoming tactics like organ-selective targeting and CRISPR-Cas gene editing are all covered in this review.

Authors

Publication Details

Journal
International Journal of Advanced Research in Science Communication and Technology
Published
2026-11-20
DOI
https://doi.org/10.48175/ijarsct-40876
Primary Topic
RNA Interference and Gene Delivery
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Lipid Nanoparticles in Drug and Gene Delivery: Current Advances and Future Perspectives

Roshan Akotkar, Dr. Vidhya Thorat, Dr. Pravin Sable, Dhanshree Badadhe Joel Chakranarayan
International Journal of Advanced Research in Science Communication and Technology
RNA Interference and Gene Delivery
article

Lipid Nanoparticles in Drug and Gene Delivery: Current Advances and Future Perspectives

Roshan Akotkar, Dr. Vidhya Thorat, Dr. Pravin Sable, Dhanshree Badadhe Joel Chakranarayan
article en

Abstract

As a cutting-edge non-viral delivery system, lipid nanoparticles (LNPs) are revolutionizing the treatment of drugs and nucleic acids. LNPs are now recognized as adaptable, clinically validated nanocarriers due to their clinical success, as evidenced by approved siRNA therapies and extensively used mRNA vaccines. In order to facilitate effective intracellular cargo release, modern LNPs employ ionizable lipids, which are neutral under physiological conditions but become positively charged in acidic endosomes. Stability, encapsulation efficiency, biodistribution, and therapeutic efficacy have all been enhanced by developments in lipid chemistry, microfluidic manufacturing, surface engineering, and artificial intelligence-assisted formulation. However, obstacles to wider use still include low tissue specificity, ineffective endosomal escape, immunogenicity, production difficulties, and long-term safety. The evolution, composition, formulation, delivery methods, therapeutic uses, clinical translation, regulatory issues, and upcoming tactics like organ-selective targeting and CRISPR-Cas gene editing are all covered in this review.

International Journal of Advanced Research in Science Communication and Technology
RNA Interference and Gene Delivery
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon